Jefferies & Co Adjusts Amcor Price Target to $43.79 From $46.15
Investment firm Jefferies & Co has revised its price target for Amcor plc, lowering it from $46.15 to $43.79.
Stocks · News reference
Jim Cramer Says Buy Uber, Calls Rockwell Automation 'One Ugly Chart' but a 'Great Long-Term Situation'
Jim Cramer recommended buying Uber, Tanger, Rockwell Automation, Amcor, and Neurocrine Biosciences. Uber and Zipline announced a partnership for autonomous delivery. Tanger and Amcor both reported better-than-expected earnings. Rockwell Automation and Neurocrine Biosciences had mixed reactions from analysts. Uber and Amcor shares fell, while Tanger, Rockwell Automation, and Neurocrine Biosciences shares all had varying degrees of movement.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Amcor plc Announces Upcoming September 2026 Quarterly Results
Amcor plc has scheduled the announcement of its financial results for the three-month period ending September 30, 2026.
Neurocrine Biosciences Presents New Research on Clinically Meaningful Health Improvements in Tardive Dyskinesia Patients
Neurocrine Biosciences announced new research establishing a 6-point improvement on the EQ Visual Analogue Scale as a benchmark for clinically meaningful change in patients with tardive dyskinesia treated with INGREZZA.
Neurocrine Biosciences Announces Publication of Expert Perspectives on Hyperphagia in Prader-Willi Syndrome
Neurocrine Biosciences announced the publication of expert perspectives in the Orphanet Journal of Rare Diseases regarding the management of hyperphagia in Prader-Willi syndrome.
Neurocrine Biosciences shares are trading higher after the company announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 in adults with mild to moderate Alzheimer's disease.
Neurocrine Biosciences Starts Phase 2 Clinical Trial Of NBI-1117567 To Treat Adults With Mild To Moderate Alzheimer's Disease
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 (NBI-'567) in adults with mild to moderate Alzheimer's disease.